Eunomia Pharma Services
All resources

Eunomia perspective · 2026-06-02 · Compliance Programmes, Audits & Training

Right-Sized Compliance Support: Meeting the Needs of Both Emerging Biotech and Global Pharma

Published by Eunomia Pharma Services · Updated

How can a biotech company outsource compliance without losing oversight?

A biotech can outsource defined compliance activities, such as material review, HCP engagement administration or disclosure preparation, while retaining a named internal owner and clear decision rights. Start with the activities and markets you actually operate in, agree the provider’s scope, and establish approval, escalation and reporting arrangements. The service should fit the company’s risks and stage of development.

What to agree before outsourcing

  1. Define the work: list markets, activities, expected volumes, exclusions and the evidence each completed task must produce.
  2. Name the owners: record who prepares, reviews, approves and escalates each activity, including decisions retained by the company.
  3. Test the handover: walk through a representative engagement or material from request to approval and record any gaps.
  4. Monitor delivery: agree turnaround measures, quality checks, exceptions reporting and a route for changing scope as the business grows.

The practical steps above are Eunomia’s operational guidance. See the source notes below for the scope of the external references.

Key Takeaways

  • Compliance programs should reflect the size, maturity, and operational complexity of an organisation.
  • Emerging biotech companies benefit most from practical foundational controls rather than overly complex systems.
  • Global pharmaceutical companies require integrated governance, oversight, and scalable operational compliance frameworks.
  • A right-sized compliance approach reduces risk while supporting business growth and agility.
  • Effective compliance should enable innovation, not slow it down.

Compliance Is Not One-Size-Fits-All

A compliance framework that works for a multinational pharmaceutical company may be completely impractical for an emerging biotech organisation. Equally, lightweight processes that support an early-stage company may not withstand the operational demands of a mature global business.

Yet many organisations struggle to find the right balance.
Some companies implement highly complex governance structures too early, creating unnecessary administrative burden and slowing decision-making. Others delay compliance investment until commercial activity increases, external scrutiny grows, or risks become visible.
Both approaches can create significant operational and reputational challenges.
The reality is that effective compliance should evolve alongside the organisation itself. The most sustainable programs are proportionate, scalable, and aligned to actual business needs.

Why Emerging Biotech Companies Face Different Compliance Challenges

Emerging biotech companies often operate in fast-moving environments where scientific innovation, funding milestones, and operational agility take priority. Teams are typically lean, responsibilities overlap, and formal governance structures may still be developing.

In many cases, compliance activities are managed alongside medical, legal, or operational functions rather than through dedicated compliance departments.

This creates a unique challenge: the organisation may already be engaging healthcare professionals, sponsoring scientific activities, or interacting with external vendors before foundational compliance processes are fully established.
For example, a biotech company preparing for its first advisory board may not yet have clear internal guidance on fair market value assessments, approval requirements, documentation standards, or engagement protocols. The activity itself may be scientifically appropriate, but gaps in governance can still create compliance exposure.
These risks are not always immediately visible. However, they often become important during partnerships, investor due diligence, inspections, or future acquisitions.
Common areas of exposure include inconsistent documentation practices, unclear approval pathways, inadequate third-party oversight, and uncertainty around promotional versus non-promotional activities.

Why Emerging Companies Should Focus on “First Things First”

For emerging biotech organisations, the objective should not be to replicate the infrastructure of a large pharmaceutical company overnight.
The priority should be establishing practical foundational controls that reduce meaningful risk while allowing the business to remain agile.

This typically starts with clearly written SOPs, defined approval pathways, and role-based training for teams interacting with healthcare professionals or external stakeholders. Even simple governance processes can significantly improve consistency, accountability, and decision-making.

Documentation is another critical area. Organisations do not need overly sophisticated systems from day one, but they do need reliable evidence of approvals, engagements, and compliance decisions. Without this foundation, even well-managed activities can become difficult to defend during audits or due diligence reviews.
Importantly, right-sized compliance is not about creating bureaucracy. It is about implementing controls that are proportionate to the organisation’s stage of growth and operational risk profile.
Companies that establish these foundations early are often better positioned to scale efficiently as their activities expand.

Global Pharma Requires Mature and Operationally Integrated Compliance

The challenges facing global pharmaceutical companies are very different.
Large organisations operate across multiple jurisdictions, business functions, and regulatory environments. Their compliance frameworks must support complex medical, commercial, and operational activities while maintaining consistency across affiliates and regions.
In these environments, the challenge is rarely the absence of governance. Instead, the focus is often on operational integration, oversight, and harmonisation.
Global organisations must balance robust controls with business efficiency. This includes managing global material review systems, overseeing third-party vendors at scale, maintaining audit readiness, and ensuring consistent interpretation of policies across markets.
As organisations mature, compliance also becomes increasingly data-driven. Metrics, monitoring programs, governance committees, and risk assessments play a larger role in supporting oversight and continuous improvement.
The expectation is no longer simply to have policies in place, but to demonstrate that compliance frameworks operate effectively in practice.

The Business Impact of Right-Sized Compliance

Well-designed compliance programs do more than reduce regulatory risk.
They improve operational clarity, strengthen decision-making, support investor confidence, and help organisations scale more effectively. They also protect corporate reputation in an industry where trust and transparency are critical.
Perhaps most importantly, right-sized compliance allows teams to focus resources where risk genuinely exists instead of creating unnecessary complexity.
For growing biotech companies, this can preserve agility while building credibility with partners and investors. For mature pharmaceutical organisations, it can improve consistency, efficiency, and governance across global operations.
In both cases, compliance should function as a strategic business enabler rather than an administrative obstacle.

How Eunomia Pharma Services Supports Both Emerging and Established Organisations

At Eunomia Pharma Services, we recognise that compliance maturity differs significantly between organisations.

Emerging biotech companies often require practical guidance to establish scalable governance foundations without introducing unnecessary complexity. This may include SOP and policy development, healthcare professional engagement frameworks, training support, third-party due diligence processes, and operational workflow design.

For global pharmaceutical companies, the focus is often on strengthening and optimising mature compliance environments. This includes support with process harmonisation, audit readiness, vendor governance, risk assessment frameworks, and operational compliance advisory services.
Our approach is always tailored to the organisation’s size, operational model, and stage of growth.
Because effective compliance is not about implementing the largest possible framework. It is about building the right framework for the business.

Frequently Asked Questions

What is right-sized compliance?

Right-sized compliance refers to compliance programs that are proportionate to a company’s size, operational complexity, and risk profile.
Overly complex systems can create unnecessary administrative burden, slow decision-making, and consume resources without meaningfully improving risk management.
Foundational compliance controls should ideally be established before significant healthcare professional engagement, scientific sponsorships, or commercial activities begin.
Yes. Effective compliance frameworks are designed to evolve alongside organisational growth, business expansion, and increasing regulatory expectations.

Whether an organisation is establishing its first governance framework or strengthening a mature global compliance program, the objective should remain the same: building practical, scalable, and effective compliance systems that support sustainable growth.

Compliance should reflect business reality, operational risk, and organisational maturity — not a generic template.

To learn how Eunomia Pharma Services can support your organisation with tailored compliance solutions, contact our team to start the conversation.

Sources and scope

External sources accessed 28 September 2026. Check the applicable country rules and current source text for a specific engagement.

Put this into practice